CHICAGO, IL and San Diego, CA - February 3, 2000
Integrated Genomics, Inc. (IG) announced today that it has entered into a research agreement with The Dow Chemical Company. Under the terms of agreement, Integrated Genomics will sequence and analyze genomes of interest to The Dow Chemical Company. Dow Chemical will also license IG's bioinformatics software package, WIT-PRO™, containing the largest genomic and biochemical databases in the market.
"Integrated Genomics and The Dow Chemical Company are a good fit. We are very pleased to be working with IG, and their established expertise in microbial genomics. We are particularly interested in the higher-end metabolic reconstruction service uniquely provided by IG," said Paul Zorner, Chief Scientist for Dow's Global Biotechnology and Bioprocessing Platform, located in San Diego, CA.
"We are happy to provide our expertise in sequencing and bioinformatics to The Dow Chemical Company. Our cutting-edge technology is invaluable for refining gene functions, for reconstructing metabolic maps, and ultimately for understanding the biology of entire species," said Robert Haselkorn, President of Integrated Genomics.
About Dow Chemical
The Dow Chemical Company is a global science and technology based company that develops and manufactures a portfolio of chemical, plastic and agricultural products and services for customers in 168 countries around the world. With annual sales of more than $18 billion, Dow conducts its operations through 15 global businesses employing 39,000 people. The company has 123 manufacturing sites in 32 countries and supplies more than 3,500 products.
About Integrated Genomics
Integrated Genomics, Inc., based in Chicago, Illinois, offers analysis of bacterial and fungal genomes, from high-throughput sequencing to sophisticated bioinformatics. The company is a recognized leader in sequence-based metabolic reconstruction and pathway design.
Yuri Nikolski, Ph.D.
Vice President, Business Development